Leukoplakia, Oral
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Bristol Myers SquibbNivolumab
Skyline TherapeuticsSBS-101
Clinical Trials (2)
Total enrollment: 33 patients across 2 trials
Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia
Start: Dec 2018Est. completion: Aug 202433 patients
Phase 2Completed
This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions
Start: Jan 2022Est. completion: May 20230
Phase 1Withdrawn
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Monoclonal Antibody is the dominant modality (100% of programs)
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.